Former Texas leader Rick Perry attended a Tyler gathering that showcased ibogaine therapy for military veterans, as KLTV reported. The fundraising gathering occurred at Willow Brook Country Club and collected over two hundred thousand dollars to support initiatives centered around the therapy for individuals dealing with post-traumatic stress disorder.

During the event, participant Dan Moran shared details of his military service and recovery. Dan Moran completed two Iraq military deployments and sustained severe injuries during a vehicle explosion. Three Marines died in the blast. Following the incident, Dan Moran spent three years healing at Brooke Army Medical Center.

"I suffered 50% third degree burns, lost my spleen, had multiple fractures in my back, inhalation injury, and was transferred to Brook Army Medical Center, where I spent three years recovering, learning how to do everything again," Dan Moran told KLTV.

Dan Moran also spoke about how he learned of the therapy through personal connections tied to the initiative. "A friend of mine, his name’s Rick Perry, gave me a call and he told me, ‘Hey, there’s a new treatment that’s out there that you need to take a look at.’ And I did. And I’ll be eternally grateful for that," Dan Moran told KLTV.

The event highlighted broader institutional and legislative efforts surrounding the treatment. Marcus Capone co-founded the Veterans Exploring Treatment Solutions nonprofit to advocate for alternative care options. On the legislative front, Cody Harris led a Texas research initiative and secured a fifty million dollar clinical trial bill to further investigate the approach. These state-level measures mirror a wider trend, as five additional states pursued comparable efforts, and the Trump administration revealed new ibogaine study funds to support federal research.

While advocates promote the potential benefits of the therapy, medical oversight remains vital for treatment safety. Specifically, potential heart rhythm risks are documented, underscoring the need for careful supervision as clinical trials and legislative initiatives move forward.